Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.

Abstract

Meningeal hemangiopericytoma is an uncommon and aggressive malignancy that, in contrast to meningiomas, shows a high propensity for local recurrence and the development of late extraneural metastases. The results of chemotherapy in advanced hemangiopericytoma have been disappointing, and they have been particularly poor in cases located in the meninges. We report a case of a heavily pretreated metastatic meningeal hemangiopericytoma in which fourth-line chemotherapy with trabectedin, a marine-derived antineoplastic agent effective in treating advanced soft tissue sarcomas, resulted in clinical benefit.

• Authors: Javier Martinez-Trufero, Jorge Alfaro, Francesc Felipo, Maria Alvarez, Julia Madani, Ana Cebollero
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 21 Issue 8 Pg. 795-8 (Sep 2010) ISSN: 1473-5741 [Electronic] England
• PMID: 20622667 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Dioxoles
• Tetrahydroisoquinolines
• Trabectedin

Topics

• Adult
• Antineoplastic Agents, Alkylating (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Dioxoles (administration & dosage, adverse effects, therapeutic use)
• Hemangiopericytoma (drug therapy, secondary)
• Humans
• Male
• Meningeal Neoplasms (drug therapy)
• Neoplasm Staging
• Tetrahydroisoquinolines (administration & dosage, adverse effects, therapeutic use)
• Trabectedin
• Treatment Outcome